Company Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) Rally 13.82%

Achillion Pharmaceuticals (NASDAQ:ACHN) has been under a strong bear grip, hence the stock is down -5.81% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 12.38% in the past 1 week. The stock has risen by 13.82% in the past week indicating that the buyers are active at lower levels, but the stock is down -4.29% in the past 4 weeks.

The company shares have rallied 0.66% from its 1 Year high price. On Dec 30, 2015, the shares registered one year high at $10.95 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $8.81 and the 200 Day Moving Average price is recorded at $8.10.

The stock has recorded a 20-day Moving Average of 7.35% and the 50-Day Moving Average is 6.07%.


Achillion Pharmaceuticals (NASDAQ:ACHN): stock turned positive on Friday. Though the stock opened at $8.84, the bulls momentum made the stock top out at $9.2 level for the day. The stock recorded a low of $8.8267 and closed the trading day at $9.14, in the green by 2.93%. The total traded volume for the day was 1,593,567. The stock had closed at $8.88 in the previous days trading.

In an insider trading activity, The officer (Chief Financial Officer), of Achillion Pharmaceuticals Inc, Fenton Mary Kay had unloaded 43,500 shares at $10.08 per share in a transaction on December 28, 2015. The total value of transaction was $438,480. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.

Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *